Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
Status:
Completed
Trial end date:
2019-07-18
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of vorinostat when given
together with sorafenib tosylate in treating patients with advanced liver cancer. Sorafenib
tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth or by blocking blood flow to the tumor.